Hypertension Clinical Trial
Official title:
Latinos Using Cardio Health Actions to Reduce Risk (LUCHAR): Effect of Omega-3 Fatty Acids on Vascular Function and Inflammation
The overall objective of LUCHAR Specific Aims 4.1 and 4.2 is to assess the additional
contribution of cardiovascular disease (CVD) risk markers to traditional biomedical risk
factors in the prediction of pre-clinical CVD. Specific Aim 4.3 will test the impact of
omega-3 fatty acid supplementation on risk markers and pre-clinical markers of CVD in
Hispanic patients.
Specific Aim 4.3: Conduct a randomized, placebo-controlled trial of the effect of omega-3
fatty acid supplementation on vascular function as measured by brachial artery reactivity
(BAR) and on circulating inflammatory markers.
Hypotheses:
1. Daily omega-3 fatty acid supplementation will improve vascular function in subjects at
high risk for CVD.
2. Daily omega-3 fatty acid supplementation will reduce inflammatory protein panel scores
in subjects at high risk for CVD.
Status | Terminated |
Enrollment | 76 |
Est. completion date | March 2012 |
Est. primary completion date | March 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Diagnosis of HTN - Hispanic or Non-Hispanic White - Age > 18 - One additional CVD risk factor - Age > 55 for males or >65 for females - DM - Dyslipidemia O TC >220 or O LDL >130 or O on statin therapy - Current smoker - Chronic kidney disease defined as GFR <60 ml/min/1.72m2 - BMI > 30 kg/m2 - Positive microalbuminuria -Able to sign consent form and willing to complete 12-month follow- up period. Exclusion criteria used for SA3/4 will also apply for Aim 4.3. These include factors rendering assessment of endothelial function unreliable, such as: - Clinically manifest CVD (including angina, myocardial infarction, surgical or percutaneous coronary revascularization, stroke, cerebrovascular revascularization, peripheral vascular disease, heart failure, or valvular heart disease - Electrocardiographic evidence of prior myocardial infarction - Known valvular heart disease of at least moderate severity - Known left ventricular systolic dysfunction (LVEF < 0.50) - End-stage renal disease - History of inflammatory disease or vasculitis (including rheumatoid arthritis, systemic lupus erythematosis, Raynaud phenomenon, or other connective tissue disease/vasculitides) - Corticosteroid therapy - Active substance abuse - Projected life-expectancy <12 months due to comorbid condition - Plans to move away from the Denver area within 12 months - Previous trauma or surgery of the brachial artery - Upper arm circumference exceeding 42 cm. Additional exclusion criteria for participation in Aim 4.3 include: - Pregnancy or breast-feeding - Known sensitivity or allergy to fish - Known sensitivity or allergy to omega-3 fatty acid supplements - Taking omega-3 fatty acid supplements in the last 2 weeks- may participate after 2 week washout - Triglycerides > 500 mg/dL. - Alanine aminotransferase (ALT) levels above 3x upper limit of normal - Not a good candidate for participation based on the opinion of the investigators. - Current therapy with a fibric acid derivative |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
United States | Denver Health and Hospital Authority | Denver | Colorado |
Lead Sponsor | Collaborator |
---|---|
Denver Health and Hospital Authority | GlaxoSmithKline, National Heart, Lung, and Blood Institute (NHLBI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Pulse Wave Velocity in Active vs. Placebo-treated Patients. | We conducted a prospective, randomized; double-blinded study of omega-3 fatty acids among 60 Latino and White hypertensive patients at risk for CVD. Patients received either 4-g omega-3 fatty acids or matched placebo daily. The principal outcome measure was change in brachial-ankle PWV. | Baseline, 3 months | No |
Secondary | Change in Lipoprotein-associated Phospholipase A2 (LpPLA2) | baseline, 3 months | No | |
Secondary | Change in hsCRP | baseline, 3 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Completed |
NCT03093532 -
A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT05529147 -
The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
|
||
Recruiting |
NCT05976230 -
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
|
||
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Completed |
NCT06008015 -
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05387174 -
Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Recruiting |
NCT05121337 -
Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension
|
N/A | |
Withdrawn |
NCT04922424 -
Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
|
Phase 1 | |
Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
Completed |
NCT05087290 -
LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
|
||
Not yet recruiting |
NCT05038774 -
Educational Intervention for Hypertension Management
|
N/A | |
Completed |
NCT05621694 -
Exploring Oxytocin Response to Meditative Movement
|
N/A | |
Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
Recruiting |
NCT05575453 -
OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure
|
N/A |